{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:51:24Z","timestamp":1791085884705,"version":"4.1.0"},"reference-count":109,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective\u2002<\/jats:bold>\n                    To characterize the frequency, reasons, risk factors, and consequences of unstructured anti\u2010retroviral treatment interruptions.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Method\u2002<\/jats:bold>\n                    Systematic review.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    Seventy studies were included. The median proportion of patients interrupting treatment was 23% for a median duration of 150\u2003days. The most frequently reported reasons for interruptions were drug toxicity, adverse events, and side\u2010effects; studies from developing countries additionally cited treatment costs and pharmacy stock\u2010outs as concerns. Younger age and injecting drug use was a frequently reported risk factor. Other risk factors included CD4 count, socioeconomic variables, and pharmacy stock outs. Treatment interruptions increased the risk of death, opportunistic infections, virologic failure, resistance development, and poor immunological recovery. Proposed interventions to minimize interruptions included counseling, mental health services, services for women, men, and ethnic minorities. One intervention study found that the use of short message service reminders decrease the prevalence of treatment interruption from 19% to 10%. Finally, several studies from Africa stressed the importance of reliable and free access to medication.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion\u2002<\/jats:bold>\n                    Treatment interruptions are common and contribute to worsening patient outcomes. HIV\/AIDS programmes should consider assessing their causes and frequency as part of routine monitoring. Future research should focus on evaluating interventions to address the most frequently reported reasons for interruptions.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-3156.2011.02828.x","type":"journal-article","created":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T05:09:06Z","timestamp":1309496946000},"page":"1297-1313","source":"Crossref","is-referenced-by-count":117,"title":["Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review"],"prefix":"10.1111","volume":"16","author":[{"given":"Katharina","family":"Kranzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.00257.x"},{"key":"e_1_2_6_3_1","unstructured":"AdeyemiA&OlaogunO(2006)Challenges to management of HIV patients in rural and urban communities in South\u2010western Nigeria. XVI International AIDS Conference. Toronto Canada."},{"key":"e_1_2_6_4_1","unstructured":"AhonkhaiA NoubaryF MunroAet\u00a0al.(2011)Not all are lost: early death care interruption loss to follow\u2010up in a large South African community treatment program. 18th Conference on Retroviruses and Opportunistic Infections. Boston USA."},{"key":"e_1_2_6_5_1","unstructured":"AmmassariA TrottaMP MarconiPet\u00a0al.(2004)Incorporating patients\u2019 suggestions in individualized intervention program for improving adherence to antiretrovirals. XV International AIDS Conference. Bangkok Thailand."},{"key":"e_1_2_6_6_1","unstructured":"AyuoP BraitsteinP NyandikoWet\u00a0al.(2008)Frequency and factors associated with loss to follow\u2010up (LTFU) and treatment interruptions (TI) among pregnant women initiating combination antiretroviral therapy (cART) in Western Kenya. XVII International AIDS Conference. Mexico City Mexico."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328340feb0"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000199825.34241.49"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f4709a"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318211b43b"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2006.22.40"},{"key":"e_1_2_6_12_1","unstructured":"BerenguerJ Perez\u2010EliasMJ BellonJMet\u00a0al.(2004)Abacavir lamivudine and zidovudine (ABC\/3TC\/ZDV) in antiretroviral\u2010naive HIV\u2010infected patients: multicenter observational cohort from Spain. XV International AIDS Conference. Bangkok Thailand."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31817dc416"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328329fc8d"},{"key":"e_1_2_6_15_1","unstructured":"BraitsteinP MwangiA Wools\u2010KaloustianKet\u00a0al.(2007)Frequency causes and factors associated with treatment interruptions (TI) among adults initiating highly active antiretroviral therapy (HAART) in Western Kenya. 4th Conference on HIV Pathogenesis Treatment and Prevention. Sydney Australia."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005790"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02918.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-009-9546-x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61027-7"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/088922202760265588"},{"key":"e_1_2_6_21_1","unstructured":"CompostellaS ZeniC AntonelliSet\u00a0al.(2005)The psychological reasons and consequences of unstructured therapy interruptions in HIV+ subjects. The 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro Brazil."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1218"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00213.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-008-9401-5"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181d91788"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09411-4"},{"key":"e_1_2_6_27_1","unstructured":"EkstrandML ChandyS StewardWTet\u00a0al.(2008)Barriers to long\u2010term maintenance of HAART adherence and viral suppression in India. XVII International AIDS Conference. Mexico City Mexico."},{"key":"e_1_2_6_28_1","doi-asserted-by":"crossref","unstructured":"EkstrandML ShetA ChandySet\u00a0al.(2010)Suboptimal adherence associated with virologic failure and resistance mutations among patients on 1st line HAART in Bandalore India. XVIII International AIDS Conference. Vienna Austria.","DOI":"10.1016\/j.inhe.2010.11.003"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062360"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013499"},{"key":"e_1_2_6_31_1","unstructured":"GandhiM AmeliN LieglerTet\u00a0al.(2004)Prevalence and predictors of treatment interruptions in a longitudinal cohort study in women. XV International AIDS Conference. Bangkok Thailand."},{"key":"e_1_2_6_32_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00042560-200205010-00014","article-title":"Impact of adherence and highly active antiretroviral therapy on survival in HIV\u2010infected patients","volume":"30","author":"Garcia De Olalla P","year":"2002","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2005.05.007"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000122601.62358.74"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000186371.95301.52"},{"key":"e_1_2_6_36_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181ca48bf","article-title":"Longitudinal analysis of patterns and predictors of changes in self\u2010reported adherence to antiretroviral therapy: Swiss HIV Cohort Study","volume":"54","author":"Glass TR","year":"2010","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"e_1_2_6_37_1","unstructured":"GonzalezA KnobelH GuelarAet\u00a0al.(2003)Risks and benefits after treatment interruption of antiretroviral therapy in the clinical practice setting. The 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris France."},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00183.x"},{"key":"e_1_2_6_39_1","unstructured":"GriersonJ ThorpeR&PittsMK(2005)Motivation and consequences of treatment interruptions from the patient perspective. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janerio Brazil."},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200205030-00012"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00436.x"},{"key":"e_1_2_6_42_1","unstructured":"HullM JoyR HoggR&MontanerJ(2006)Modelling CD4 cell count decline during treatment interruption stratified by pre\u2010treatment CD4 nadir. XVI International AIDS Conference. Toronto Canada."},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.4.462"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60693-5"},{"key":"e_1_2_6_45_1","unstructured":"KaptueL KemkuiningJ KenmogneP&KaptueB(2002)Follow up of AIDS patients on antiretroviral therapy in Yaounde\u2010Cameroon. XIV International AIDS Conference. Barcelona Spain."},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283430013"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318198a800"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203080-00012"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2009.00696.x"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.07.008"},{"key":"e_1_2_6_51_1","unstructured":"KouanfackC MontavonC LaurentCet\u00a0al.(2008)Evaluation of virological outcome and ARV drug resistance in the national ART program in Cameroon. XVII International AIDS Conference. Mexico City Mexico."},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181f275fd"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200303070-00022"},{"key":"e_1_2_6_54_1","unstructured":"LaherF MoodleyN MaphuthaM McintyreJ&MohapiL(2007)Virologic suppression after hyperlactataemia\u2010related treatment interruption in an African setting. 4th IAS Conference on HIV Pathogenesis Treament and Prevention. Sydney Australia."},{"key":"e_1_2_6_55_1","unstructured":"LandmanR MatheronS BouvetEet\u00a0al.(2003)Effects of antiretroviral treatment interruption in chronic stable patients with virological success. The 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris France."},{"key":"e_1_2_6_56_1","unstructured":"LazarF LucaAE ConstantinCet\u00a0al.(2010)Factors influencing treatment adherence of young people. XVIII International AIDS Conference. Vienna Austria."},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1086\/522762"},{"key":"e_1_2_6_58_1","first-page":"320","article-title":"Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study","volume":"38","author":"Li X","year":"2005","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31819675e9"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct0805-282"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.046060"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2008.02170.x"},{"key":"e_1_2_6_63_1","unstructured":"MartsinovskayaV KobyshchaI KruglovY&WellerG(2010)Increasing mortality despite ART scale\u2010up: structure and causes of death in patients with HIV infection in Ukraine. XVIII International AIDS Conference. Vienna Austria."},{"key":"e_1_2_6_64_1","unstructured":"MbanyaDN(2003)Experiences monitoring AIDS patients on antiretroviral therapy in a resource\u2010limited setting. The 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris France."},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030438"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101260-00007"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2005.21.743"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2009.00779.x"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f2d760"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.3109\/13550281003767710"},{"key":"e_1_2_6_71_1","unstructured":"MurriR DrapeauCMJ De LucaA FantoniM&CaudaR(2002)Non\u2010structured treatment interruptions are associated with detectable HIV RNA in people taking NNRTI. XIV International AIDS Conference. Barcelona Spain."},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2007.0248"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000186019.47297.0d"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181b9e94d"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328333ad61"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2006.74.915"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000147522.34369.12"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32802e6bfa"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007115"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1086\/383572"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002783"},{"key":"e_1_2_6_84_1","doi-asserted-by":"publisher","DOI":"10.1086\/651419"},{"key":"e_1_2_6_85_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013414"},{"key":"e_1_2_6_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0755-4982(05)73403-5"},{"key":"e_1_2_6_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834380c1"},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301030-00019"},{"key":"e_1_2_6_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181ba1c48"},{"key":"e_1_2_6_90_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040298"},{"key":"e_1_2_6_91_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-1086"},{"key":"e_1_2_6_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2006.03.029"},{"key":"e_1_2_6_93_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02125-09"},{"key":"e_1_2_6_94_1","doi-asserted-by":"crossref","unstructured":"SchrootenW PelgromJ VandenbruaeneMet\u00a0al.(2004)Five\u2010year immunologic outcome of highly active antiretroviral treatment in a clinical setting: results from a single HIV treatment centre. XV International AIDS Conference. Bangkok Thailand.","DOI":"10.1258\/0956462041558267"},{"key":"e_1_2_6_95_1","first-page":"236","article-title":"CD4\u2003+\u2003 guided antiretroviral treatment interruption in HIV infection: a meta\u2010analysis","volume":"10","author":"Seminari E","year":"2008","journal-title":"AIDS Reviews"},{"key":"e_1_2_6_96_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200411010-00003"},{"key":"e_1_2_6_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0248-8663(03)00067-5"},{"key":"e_1_2_6_98_1","doi-asserted-by":"publisher","DOI":"10.1086\/499044"},{"key":"e_1_2_6_99_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-4-26"},{"key":"e_1_2_6_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203290-00010"},{"key":"e_1_2_6_101_1","doi-asserted-by":"publisher","DOI":"10.1086\/379514"},{"key":"e_1_2_6_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000230321.85911.db"},{"key":"e_1_2_6_103_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318186ead2"},{"key":"e_1_2_6_104_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200109280-00030"},{"key":"e_1_2_6_105_1","unstructured":"UhagazeB NdourT SowPS&RahlenbeckS(2006)Why are drugs not taken? A study into ARV\u2010therapy interruption in Dakar Senegal. XVI International AIDS Conference. Toronto Canada."},{"key":"e_1_2_6_106_1","unstructured":"Van ValkengoedIG PodganyK GrasLet\u00a0al.(2003)Therapy interruptions in patients with CD4\u2003+\u2003 T\u2010cell counts >500 while on HAART. The 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris France."},{"key":"e_1_2_6_107_1","unstructured":"WenkelJ Van Boogard DenW O\u2019brianDet\u00a0al.(2006)Adverse consequences of user fees for patients started on antiretroviral therapy (ART) in the governmental HIV\u2010programs in Nigeria. XVI International AIDS conference. Toronto Canada."},{"key":"e_1_2_6_108_1","first-page":"56","article-title":"Long\u2010term consequences of treatment interruptions in chronically HIV\u20101\u2010infected patients","volume":"10","author":"Wolf E","year":"2005","journal-title":"European Journal of Medical Research"},{"key":"e_1_2_6_109_1","doi-asserted-by":"publisher","DOI":"10.1086\/338726"},{"key":"e_1_2_6_110_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1564"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-3156.2011.02828.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-3156.2011.02828.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T18:06:21Z","timestamp":1698775581000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-3156.2011.02828.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":109,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1111\/j.1365-3156.2011.02828.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-3156.2011.02828.x","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}